Adjuvant irinotecan-apatinib therapy for recurrent/metastatic gastric cancer after surgery: A real-world evaluation

doi:10.4240/wjgs.v18.i3.114569

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 3

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (39)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-5) series.

Item

Count

PDF

HTML

Figures (1-2)

Tables (1-5)

Sum=21

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=11

Mar 27, 2026 (publication date) through Mar 30, 2026

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Surg. Mar 27, 2026; 18(3): 114569
Published online Mar 27, 2026. doi: 10.4240/wjgs.v18.i3.114569

Adjuvant irinotecan-apatinib therapy for recurrent/metastatic gastric cancer after surgery: A real-world evaluation

Jun-Feng Shi, Hui Xu, Jin-Feng Gao, Jian-Bin Wu

Jun-Feng Shi, Department of Oncology, Nanjing First Hospital, Nanjing 210006, Jiangsu Province, China

Hui Xu, Department of Oncology, Nanjing Lishui District People’s Hospital, Nanjing 211200, Jiangsu Province, China

Jin-Feng Gao, Department of Oncology, Nanjing Jiangbei Hospital, Nanjing 210000, Jiangsu Province, China

Jian-Bin Wu, Department of Human Resources, Jiangsu Hengrui Medicine Co., Ltd, Shanghai 200122, China

Author contributions: Wu JB designed the research and wrote the first manuscript; Shi JF, Xu H, Gao JF and Wu JB contributed to conceiving the research and analyzing data; Wu JB conducted the analysis and provided guidance for the research; all authors reviewed and approved the final manuscript.

Institutional review board statement: The study was approved by the Institutional Review Board of Nanjing First Hospital.

Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.

Conflict-of-interest statement: The authors state that they have no conflicts of interest.

Data sharing statement: No additional data are available.

Corresponding author: Jian-Bin Wu, MD, Department of Human Resources, Jiangsu Hengrui Medicine Co., Ltd, No. 1288 Haike Road, Shanghai 200122, China. 18205137866@163.com

Received: November 18, 2025
Revised: December 22, 2025
Accepted: January 12, 2026
Published online: March 27, 2026
Processing time: 129 Days and 3.6 Hours

Core Tip

Core Tip: This study presents a real-world data analysis of clinical efficacy outcomes associated with irinotecan-apatinib adjuvant therapy among patients with postoperative recurrent/metastatic gastric cancer (RMGC). We included 124 postsurgical RMGC patients treated from April 2021 to April 2024, all of whom received the S-1 (via intravenous infusion) plus oxaliplatin (via oral administration; S-1+oxaliplatin) regimen. The irinotecan-apatinib adjuvant therapy for these patients demonstrated significant clinical advantages in inhibiting inflammation and serum tumor markers while improving quality of life, which could be a better option for these patients.